Literature DB >> 9312085

The role of the amino terminus in the kinetics and assembly of alpha-hemolysin of Staphylococcus aureus.

S Vandana1, M Raje, M V Krishnasastry.   

Abstract

The nature of the involvement of an intact NH2 terminus in the assembly of alpha-hemolysin of Staphylococcus aureus was reinvestigated. For the first time, a deletion of the first four amino acids at the NH2 terminus of alpha-hemolysin yielded a novel mutant that undergoes all of the conformational changes to form a lytic pore. The experimental evidence shows unequivocally that the mutant toxin forms heat- and sodium dodecyl sulfate-stable heptameric oligomers. The concentration required to achieve 50% lysis of red blood cells is around 58-116 ng/ml, and the time taken to achieve lysis to the same extent as that of intact toxin is considerably longer. Transmission electron microscopic studies also suggest that the pores formed by this deletion mutant are similar to those by the full-length toxin. This is in contrast to the previously reported 2- and 11-amino acid deletions that failed to proceed further from a presumed prefinal nonlytic pore to a lytic pore. Studies on the kinetics of assembly indicate that this mutant can form heat- and sodium dodecyl sulfate-stable oligomers as fast as full-length alpha-hemolysin but that pore opening is slowed down. The data strongly suggest that these amino acids (Ala-Asp-Ser-Asp) are involved in the final stages of assembly of alpha-hemolysin in target membranes.

Entities:  

Mesh:

Substances:

Year:  1997        PMID: 9312085     DOI: 10.1074/jbc.272.40.24858

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  9 in total

Review 1.  Exotoxins of Staphylococcus aureus.

Authors:  M M Dinges; P M Orwin; P M Schlievert
Journal:  Clin Microbiol Rev       Date:  2000-01       Impact factor: 26.132

2.  Channel-forming abilities of spontaneously occurring alpha-toxin fragments from Staphylococcus aureus.

Authors:  Beatrix Vécsey-Semjén; Young-Keun Kwak; Martin Högbom; Roland Möllby
Journal:  J Membr Biol       Date:  2010-03-26       Impact factor: 1.843

3.  Dissecting the self-assembly kinetics of multimeric pore-forming toxins.

Authors:  A A Lee; M J Senior; M I Wallace; T E Woolley; I M Griffiths
Journal:  J R Soc Interface       Date:  2016-01       Impact factor: 4.118

Review 4.  Potent and tumor specific: arming bacteria with therapeutic proteins.

Authors:  Nele Van Dessel; Charles A Swofford; Neil S Forbes
Journal:  Ther Deliv       Date:  2015-03

5.  Studies on recombinant single chain Jacalin lectin reveal reduced affinity for saccharides despite normal folding like native Jacalin.

Authors:  Anagh A Sahasrabuddhe; Sushama M Gaikwad; M V Krishnasastry; M Islam Khan
Journal:  Protein Sci       Date:  2004-12       Impact factor: 6.725

6.  Molecular characterization of tlyA gene product, Rv1694 of Mycobacterium tuberculosis: a non-conventional hemolysin and a ribosomal RNA methyl transferase.

Authors:  Aejazur Rahman; Saumya S Srivastava; Amita Sneh; Neesar Ahmed; Musti V Krishnasastry
Journal:  BMC Biochem       Date:  2010-09-20       Impact factor: 4.059

Review 7.  Molecular features of the cytolytic pore-forming bacterial protein toxins.

Authors:  J E Alouf
Journal:  Folia Microbiol (Praha)       Date:  2003       Impact factor: 2.629

8.  A bacteriocin-based antimicrobial formulation to effectively disrupt the cell viability of methicillin-resistant Staphylococcus aureus (MRSA) biofilms.

Authors:  Christian Kranjec; Kirill V Ovchinnikov; Torstein Grønseth; Kumar Ebineshan; Aparna Srikantam; Dzung B Diep
Journal:  NPJ Biofilms Microbiomes       Date:  2020-12-02       Impact factor: 7.290

9.  Membrane bound monomer of Staphylococcal alpha-hemolysin induces caspase activation and apoptotic cell death despite initiation of membrane repair pathway.

Authors:  Saumya S Srivastava; Satyabrata Pany; Amita Sneh; Neesar Ahmed; Aejazur Rahman; Krishnasastry V Musti
Journal:  PLoS One       Date:  2009-07-21       Impact factor: 3.240

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.